Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

ClinicalTrials.gov ID: NCT00683475

Public ClinicalTrials.gov record NCT00683475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy

Study identification

NCT ID
NCT00683475
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
138 participants

Conditions and interventions

Interventions

  • IMC-A12 Biological
  • Mitoxantrone Drug
  • Prednisone Drug
  • IMC-1121B (ramucirumab) Biological

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2008
Primary completion
Aug 31, 2011
Completion
Aug 31, 2011
Last update posted
Oct 15, 2014

2008 – 2011

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
31
Facility City State ZIP Site status
ImClone Investigational Site La Jolla California 92093
ImClone Investigational Site New Haven Connecticut 06520
ImClone Investigational Site Boca Raton Florida 33486
ImClone Investigational Site Port Saint Lucie Florida 34952
ImClone Investigational Site Atlanta Georgia 30318
ImClone Investigational Site Chicago Illinois 60611
ImClone Investigational Site Chlcago Illinois 60637
ImClone Investigational Site Evanston Illinois 60201
ImClone Investigational Site Maryville Illinois 62062
ImClone Investigational Site Cedar Rapids Iowa 52402
ImClone Investigational Site Metairie Louisiana 70006
ImClone Investigational Site Ann Arbor Michigan 48109
ImClone Investigational Site Rochester Minnesota 55905
ImClone Investigational Site St Louis Missouri 63110
ImClone Investigational Site Billings Montana 59101
ImClone Investigational Site Roseland New Jersey 07068
ImClone Investigational Site Buffalo New York 14263
ImClone Investigational Site East Setauket New York 11733
ImClone Investigational Site New York New York 10016
ImClone Investigational Site New York New York 10019
ImClone Investigational Site New York New York 10021
ImClone Investigational Site New York New York 10032
ImClone Investigational Site Durham North Carolina 27710
ImClone Investigational Site Cleveland Ohio 44195
ImClone Investigational Site Philadelphia Pennsylvania 19111
ImClone Investigational Site Pittsburgh Pennsylvania 15232
ImClone Investigational Site Greenville South Carolina 29605
ImClone Investigational Site Knoxville Tennessee 37920
ImClone Investigational Site Nashville Tennessee 37203
ImClone Investigational Site Abilene Texas 79606
ImClone Investigational Site Dallas Texas 75246
ImClone Investigational Site Houston Texas 77030-4009
ImClone Investigational Site Houston Texas 77030
ImClone Investigational Site Seattle Washington 98104
ImClone Investigational Site Seattle Washington 98109
ImClone Investigational Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00683475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2014 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00683475 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →